BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said EMA is reviewing its MAA for Jyseleca filgotinib to treat ulcerative colitis. The partners are seeking the JAK inhibitor’s approval...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Feb 9, 2018
Financial News

CBMG raises about $31M for gene therapy in China

Sailing Capital Overseas Investment Ltd. and its affiliates invested $30.5 million in cell therapy company Cellular Biomedicine Group Inc. (NASDAQ:CBMG) through the sale of 1.7 million shares at $17.80 in a private placement. CBMG said...
BioCentury | Jan 5, 2018
Financial News

Cellular Biomedicine raises $14.5M

Cell therapy company Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said on Dec. 28, 2017, it raised $14.5 million through the sale of 1.2 million shares at $12 across two private placements. Investors included Maplebrook, Windsor Capital,...
BioCentury | Dec 29, 2017
Financial News

Cellular Biomedicine raises $14.5M

Cell therapy company Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said Thursday it raised $14.5 million through the sale of 1.2 million shares at $12 across two private placements. Investors included Maplebrook, Windsor Capital, interim CEO Bizuo...
BioCentury | Dec 6, 2016
Clinical News

C-CAR011: Ph I CARD-1 started

Cellular began the dose-escalation, Chinese Phase I CARD-1 trial to evaluate 0.8, 2.5 and 5×10 6 cells/kg C-CAR011 given over 3 infusions in 9 patients. Patients will receive 10% of the selected dose on day...
BioCentury | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Stearoyl-CoA desaturase-1 (SCD1)

...disorders and cancers. In mice, knockout of the negative SIRT1 regulator deleted in breast cancer 1 ( DBC1 ; CCAR2...
...compared with normal DBC1 expression, whereas double-knockout of DBC1 and SCD1 reversed the effects of DBC1...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Deleted in breast cancer 1 (DBC1; CCAR2); forkhead box P3 (FOXP3)

...and mouse studies suggest inhibiting DBC1 could help treat autoimmune diseases. In vitro studies identified DBC1...
...could include identifying roles for DBC1 in other models of autoimmune disease. TARGET/MARKER/PATHWAY: Deleted in breast cancer 1 (DBC1; CCAR2...
BioCentury | Jan 8, 1996
Strategy

Notes of gratitude

Commentary Notes of gratitude Today begins the fourth year of BioCentury, The Bernstein Report on BioBusiness. Happily, BioCentury has accomplished the bulk of its objectives for the first three years, and succeeded in places that...
Items per page:
1 - 10 of 10